Pharming Group N.V. (0QCO)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 1.074 |
|---|---|
| 52-week range | 0.823 – 1.827 |
| Return, 1 month / 3 months | +15.9% / −4.0% |
| Return, 1 year / 3 years | −7.1% / −3.4% |
| Trend | Below its 200-day average |
| RSI (14) | 74 |
| Volatility (1 year) | 60.6% |
| Worst drawdown (1 year) | -52.6% |
| Average daily value traded | 0.78M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pharming Group is a biopharmaceutical company based in the Netherlands that develops and makes protein-based medicines for rare diseases. Its main product is a recombinant treatment for hereditary angioedema, a genetic condition that causes sudden swelling, and the company also works on therapies for other immune and inflammatory disorders. Its customers are mainly hospitals, specialist physicians and patients in Europe and North America, and it handles manufacturing and commercial supply itself.
Pharming Group N.V. trades under the code 0QCO on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pharming Group N.V. (0QCO) trades on the London Stock Exchange in UK. It last closed at EUR 1.074 on 27 October 2026.
Its price-based Market X-Ray is 26 out of 100 (a weak price profile), ranking 3,230 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.1% and over the last three months it fell 4.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 18 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.1% | ||
| From 52-week high | -38.1% | ||
| Momentum | 26 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -4.0% | ||
| 6-month return | -24.5% | ||
| 12-month return, skipping the last month | -19.8% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 60.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -52.6% | ||
| Liquidity | 50 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.78M EUR | ||
| Zero-volume days | 6.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +26.0% |
|---|---|
| 1 month | +15.9% |
| 3 months | −4.0% |
| 6 months | −24.5% |
| 1 year | −7.1% |
| 3 years | −3.4% |
| 5 years | +37.0% |
Signals
| 50-day / 200-day average | 0.934 / 1.194 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.141 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.